1	Genotype-phenotype discrepancy among family members
2	carrying a novel glucokinase mutation: insights into the
3	interplay of GCK-MODY and insulin resistance
4	Shuhui Ji ^{1,#} , Hua Shu ^{1,#} , Hongqiang Zhao ^{2,3,#} , Yuanyuan Ye ¹ , Xuan Liu ¹ , Shanshan
5	Chen ¹ , Ying Yang ¹ , Wenli Feng ¹ , Jingting Qiao ¹ , Jinyang Zhen ¹ , Xiong Yang ^{2,3} , Ziyue
6	Zhang ¹ , Yu Fan ¹ , Yadi Huang ¹ , Qing He ¹ , Minxian Wang ^{2,3,4,5,6,7,‡} , Kunlin Wang ^{1,‡} ,
7	Ming Liu ^{1,‡}
8	
9	¹ Department of Endocrinology and Metabolism, Tianjin Medical University General
10	Hospital, Tianjin, 300052, China
11	² National Genomics Data Center, China National Center for Bioinformation, Beijing,
12	China
13	³ Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
14	⁴ College of Future Technology, Sino-Danish College, University of Chinese Academy
15	of Sciences, Beijing, 100049, China.
16	⁵ Department of Cardiovascular Surgery, Zhongnan Hospital of Wuhan University,
17	Wuhan 430071, China

18 ⁶Hubei Provincial Engineering Research Center of Minimally Invasive Cardiovascular NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19 Surgery, Wuhan 430071, China

20	⁷ Wuhan Clinical Research Center for Minimally Invasive Treatment of Structural
21	Heart Disease, Wuhan 430071, China
22	[#] Authors contribute equally to the work.
23	[‡] To whom correspondence may be addressed. Ming Liu, Department of
24	Endocrinology and Metabolism, Tianjin Medical University General Hospital, #154
25	Anshan Road, Heping District, Tianjin, 300052, China. Email: mingliu@tmu.edu.cn;
26	Kunling Wang, email: zp-sd@126.com; Minxian Wang, email: wangmx@big.ac.cn
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	

37 Abstract

38 Aims/Hypothesis: Heterozygous inactivating mutations in the glucokinase (GCK) gene are known to cause maturity-onset diabetes of the young (GCK-MODY). We 39 identified a novel variant of uncertain significance (VUS) GCK mutation (c.77A>T, 40 p.Q26L) in two family members presenting markedly different severities of diabetic 41 phenotypes. This study aimed to elucidate the potential diabetogenic effect of GCK-42 Q26L and to explore the mono- and poly-genetic background attributing to different 43 diabetes phenotypes. 44 Methods: Whole-exome sequencing (WES) and genetic analyses, including 45 polygenic risk score (PRS) assessments, were performed in three members of a family 46 with early-onset diabetes. To elucidate the impact of the GCK-Q26L mutation on 47 glucose homeostasis, a global knock-in mouse model harboring this mutation in both 48 49 heterozygous and homozygous states was generated. Insulin content and insulin secretion response to glucose and potassium were evaluated in isolated islets. 50 Furthermore, the effects of dorzagliatin (a glucokinase activator, GKA) and liraglutide 51 (a glucagon like peptide 1 receptor agonist, GLP-1RA) on glucose tolerance and 52 insulin secretion were assessed in GCK-Q26L mutant mice. 53

54 **Results:** The proband, who inherited the GCK-Q26L mutation from her father 55 (presenting with non-progressive, mildly elevated blood glucose), exhibited severe 56 diabetic phenotypes including polydipsia, polyuria, polyphagia, weight loss, and

ketosis, accompanied by significant dyslipidemia. Genetic analyses revealed that the 57 proband's severe phenotypes and metabolic profiles were associated with a high 58 59 polygenic risk score (PRS) for insulin resistance that was inherited from her mother. Global heterozygous GCK-Q26L knock-in mice showed a mild increased fasting 60 blood glucose, impaired glucose tolerance (IGT), and decreased serum insulin. 61 62 Homozygous GCK-Q26L mice presented more severe phenotypes compared to their heterozygous counterparts, confirming the diabetogenic nature of the GCK-Q26L 63 mutation. Further analyses indicated that GCK-Q26L did not affect insulin sensitivity 64 and islet insulin content. However, GCK-Q26L blunted islet responsiveness to 65 different glucose concentrations and markedly impaired glucose-stimulated insulin 66 secretion (GSIS) without affecting potassium chloride-stimulated insulin secretion 67 (KSIS) and glucose inhibitory effects on glucagon secretion. Both GKA and GLP-68 1RA enhanced insulin secretion and improved glucose tolerance in mutant mice. 69

Conclusions/Interpretation: This study demonstrates that GCK-Q26L is a GCK-MODY causing mutation. The interplay of GCK-Q26L with a high PRS for insulin resistance contributes to severe diabetic phenotypes. The findings not only expend the list of GCK-MODY causing mutations originally classified as VUS mutations, but also provides insights into interactions of GCK-MODY with polygenic risks of type 2 diabetes, highlighting the importance of considering polygenic backgrounds in the assessment and management of monogenic diabetes.

77 Keywords: monogenic diabetes, glucokinase, GCK-MODY, insulin resistance,

78 polygenic risk score (PRS)

79

80	Research	in	Context

- 81 What is already known about this subject?
- 82 Heterozygous inactivating mutations in the GCK gene cause GCK-MODY, an
- autosomal dominant disorder characterized by mild hyperglycemia present from birth.
- 84 Insulin resistance can be influenced by multiple genetic polymorphisms, contributing
- to varying diabetes phenotypes.
- 86 What is the key question?
- 87 Is the newly discovered GCK mutation pathogenic?
- 88 Do the interactions between the GCK mutation and PRS for insulin resistance
- 89 influence the phenotypic variability in patients carrying GCK-MODY?
- 90 What are the new findings?
- 91 The study demonstrates GCK-Q26L impairs GSIS and causes diabetes, establishing it
- as a novel GCK-MODY causing mutation originally classified as a VUS mutation.
- 93 The GCK-Q26L knock-in mouse line replicates phenotypes of GCK-MODY in
- 94 humans, establishing it as an excellent model for GCK-MODY.

95	The phenotypic variability in patients with GCK-MODY can be significantly
96	influenced by high-risk genetic predisposition of type 2 diabetes.
97	Both GKA and GLP-1RA enhance insulin secretion and improve glucose tolerance in
98	GCK-Q26L mutant mice, suggesting that they are favorite options for treatment of
99	patients with GCK-MODY and insulin resistance.
100	How might this impact clinical practice in the foreseeable future?
101	Recognizing atypical presentations of monogenic diabetes influenced by polygenic
102	factors can enhance diagnostic accuracy and personalized management.

- 103 Genetic testing and polygenic risk score assessments can help identify patients at
- 104 higher risk of severe phenotypes, allowing for earlier and more targeted interventions.

105

106 Background

107 Glucokinase (GCK), a key enzyme in the glycolytic pathway, plays a critical role in 108 glucose metabolism. It acts as a glucose sensor in pancreatic β cells and regulates 109 insulin secretion in response to blood glucose levels [1, 2]. The unique kinetic 110 properties of GCK make it ideal for this regulatory role, as it responds to even small 111 changes in glucose concentration within the physiological range [2, 3]. Heterozygous 112 inactivation mutations of GCK are known to cause maturity-onset diabetes of the 113 young type 2 (MODY 2, also known as GCK-MODY), an autosomal dominant form

of diabetes. These GCK inactivation mutations impair enzymatic activity, affecting 114 glucose sensing of pancreatic β cells, resulting in a higher set point for insulin 115 116 secretion, and therefore leading to mild and non-progressive elevated fasting blood glucose (FBG) from an early age [4, 5]. Notably, unlike other types of diabetes, GCK-117 MODY does not typically increase the risks of chronic micro- and macrovascular 118 complications of diabetes [6]. Therefore, the current recommendations for the 119 management of GCK-MODY emphasize lifestyle management and regular blood 120 glucose monitoring rather than active treatment with hypoglycemic agents [6, 7]. 121 However, the clinical presentation of GCK-MODY can vary significantly among 122 individuals, even within the same family. The underlying mechanisms for this 123 variability remain incompletely understood. 124

Insulin resistance associated with multiple genetic and environmental factors is a key 125 126 feature of type 2 diabetes (T2D) [8]. Recent studies have identified various genetic polymorphisms contributing to insulin resistance, each adding a small risk but 127 cumulatively having a significant impact [9]. A high polygenic risk score (PRS) for 128 129 insulin resistance aggregates the effect of numerous risk alleles, increasing the likelihood of T2D development [10, 11]. Additionally, a high PRS for T2D may also 130 interact with monogenic diabetes causing mutations, leading to atypical and severe 131 diabetic phenotypes that challenge the traditional approaches for classification and 132 management of different types of diabetes [8, 12-14]. Understanding the interaction 133 between these genetic factors is crucial for developing personalized treatment 134

135 strategies [15].

136	In this study, we identified a novel variant of uncertain significance (VUS) GCK
137	mutation (c.77A>T, p.Q26L) in two members of a family exhibiting markedly
138	different severities of diabetic phenotypes. A global knock-in mouse model
139	established that GCK-Q26L impaired insulin secretion of β cells response to glucose
140	and caused an increase of FBG and an impairment of glucose tolerance, thereby
141	confirming this mutation is a GCK-MODY causing mutation. Genetic analyses
142	revealed the interplay between the GCK-MODY mutation and a high PRS for insulin
143	resistance contributed to the severe diabetic phenotypes in the proband carrying GCK-
144	Q26L. The study not only expends the list of GCK-MODY causing mutations
145	originally classified as VUS mutations, but also highlights genetic bases underlying
146	phenotype heterogeneities of patients with monogenic diabetes.

147

148 Materials and Methods

Patients. The clinical information of the proband and her family members was detailed in Table 1, collected and documented in Tianjin Medical University General Hospital. Informed consent was obtained from all family members. The study was approved by the Tianjin Medical University General Hospital Ethics Committee (IRB2017-047-01).

154 Genetic Testing and Analyses. DNA was extracted from proband's white blood cells

for targeted gene capture, followed by whole-exome sequencing (WES) utilizing 155 massive parallel next-generation sequencing (NGS). The identified GCK gene 156 mutation was further confirmed by Sanger sequencing, the primers for the forward-157 5'-TGTGGGGGGGAGATGCCCCG-3' 5'-158 and reverse-strand were and ACCAGAGGAGCCAAGGGTGAG-3', respectively. Members of the proband's 159 160 family (father, mother and grandfather) were recruited and checked for the mutation using Sanger sequencing. Furthermore, the family members (father and mother) also 161 underwent WES sequencing. 162

Definitions for Insulin Resistance. Insulin resistance (IR) was measured as the ratio of triglycerides (TG) to high-density lipoprotein cholesterol (HDL-C) as described elsewhere [9, 16-19] (ESM Fig. 4). To correct the potential effect of cholesterol lowering medications, we adjusted the levels of TG and HDL-C before calculating IR with detailed adjustment in ESM Table 4.

Genotype quality control and imputation. The proband trios were genotyped by Affymetrix Axiom whole-genome Asian Screening Array (ASA Array) with calling rate > 99%. Kingship (ESM Table1) and sex (ESM Table2) were further validated with genetically inferred ones. The data was merged with non-close related samples from the 1000 Genomes Project with ambiguous variants (A/T or G/C alleles) removed. This was followed by a series of quality controls in samples with a missingness rate > 5%, or heterozygosity out of 5 standard deviations were excluded,

175	and variants with a missing rate $> 1\%$ or Hardy-Weinberg equilibrium with a P-value
176	< 1 \times 10 ⁻⁶ were excluded. Then, principal component analysis (PCA) was
177	conducted, and ancestry was inferred by the PCA clusters. Finally, the genotype was
178	further imputed on the TOPMed imputation server [20] (ESM Fig. 3), and variants
179	with imputation quality score (INFO) < 0.8 were removed in subsequent analysis.

180 PRS assessment. We directly utilized the polygenic scores model for insulin resistance developed by Lotta et al.[8] from the PGS Catalog and calculated the PRS 181 for our datasets together with 1000 Genomes Project East Asian samples by PLINK 182 2.0 [21]. To confirm the association between PRS and IR, we also calculated the PRS 183 for the samples (424,068 passed quality control) from the UK Biobank (ESM Table 3) 184 under application number 89885, following the same procedures. The PRS was 185 further corrected by the value of principal components (PCs) for potential population 186 187 structure and batch effects and standardized to normal distribution for further statistical analysis. 188

Mice. We commissioned GemPharmatech Co., Ltd. to create a global knock-in GCK-Q26L mouse model. The Q26L site-directed mutagenesis was introduced in exon 2 of mouse GCK-201, changing the codon for the 26th amino acid from CAG to CTG and inserting MYC before the stop codon (ESM. Fig.1a). All mice were bred on a C57BL/6J background and housed in temperature (22–25 °C) and humidity (55 \pm 5%) controlled rooms with a 12-hour light/dark cycle. All animal experimental protocols

were approved by the Internal Animal Welfare Committee at Chu Hsien-I Memorial
Hospital (Metabolic Diseases Hospital) of Tianjin Medical University.

Glucose and insulin tolerance. Mice were fasted for 6 hours before intraperitoneal 197 glucose tolerance tests (IPGTT). Glucose was administered via intraperitoneal 198 injection at 2 g/kg body weight. Blood glucose was measured from the tail vein at 0, 199 200 15, 30, 60, and 120 minutes using an automated glucose meter (Roche, ACCU-CHEK, Germany). ELISA kits were used to measure plasma insulin (EZassay, China), and 201 glucagon (Ruixin, China). For the intraperitoneal insulin tolerance test (IPITT), after a 202 4-hour fast, mice received an intraperitoneal injection of 0.7 U/kg body weight of 203 insulin (Aspart, Novo Nordisk A/S, Denmark). Dorzagliatin (Desano, China) and 204 Liraglutide (Solarbio, China) were administered to mice by gavage or intraperitoneal 205 injection, respectively, 90 minutes before the start of the IPGTT. 206

Measurement of insulin and glucagon secretion. Islet isolation, glucose-stimulated 207 insulin secretion (GSIS), and potassium-stimulated insulin secretion (KSIS) were 208 performed as previously described [22], glucose-inhibited glucagon secretion was 209 performed simultaneously with GSIS. For the dose-dependent effects of glucose on 210 insulin secretion, isolated pancreatic islets were sequentially cultured in Krebs-Ringer 211 bicarbonate HEPES (KRBH) buffer with glucose concentrations of 2.8 mM, 3.3 mM, 212 4.5 mM, 5.6 mM, and 7 mM for 2 hours each. After incubation, supernatants were 213 214 collected, and the islets were homogenized. Secreted insulin and islet insulin content

215 were measured using ELISA kits (EZassay, China). The secretion efficiency was calculated with secreted insulin in the media normalized to islet insulin content. 216 Islet perfusion assays. Islet perfusion assays were performed as previously described 217 [22]. The liquid input flow rate was 150 µl/min, with samples collected every minute. 218 Insulin secretion at each time point was quantified using the Wide Range Insulin 219 220 Assay Kit (EZassay, China) according to the manufacturer's instructions. 221 Western blot analysis. Equal amounts of islet proteins were loaded onto 4-12% NuPage gradient gels (Thermo, USA), while other tissues were loaded onto 12.5% 222 gels (US EVERBRIGHT, China). The antibodies used in this study were as follows: 223 224 anti-GCK (Cat: A00884-1, BOSTER, China), anti-c-MYC (Cat: RMYC-45A-2, ICL, USA), anti-GAPDH (Cat: AC033, Abclonal, China), anti-insulin (homemade). 225 Immunofluorescence. Mouse pancreas was fixed, sectioned, and stained with 226 different primary antibodies followed by Alexa-Fluor-conjugated secondary 227 antibodies. The antibodies used in this study were as follows: anti-insulin 228 (homemade), anti-glucagon (Cat: G2654, Sigma, USA), anti-somatostatin (Cat: 229

ab30788, abcam, USA). Fluorescent images were visualized using an Axio Imager

231 M2 microscope (Carl Zeiss, Germany).

Statistics. All experiments were performed independently at least three times. Data
are presented as means ± SEM. Statistical analyses were conducted using GraphPad
Prism 8 software. An unpaired Student's t-test was used for data analysis, with a

threshold of P < 0.05 to declare statistical significance.

236

237 **Results**

238	Identification of a novel variant of uncertain significance (VUS) GCK mutation
239	in a family with early onset diabetes. In the clinic, we observed a special case of
240	diabetes. The female proband was diagnosed with diabetes at age teens, presenting
241	with polydipsia, polyuria, polyphagia, weight loss, and ketosis. Her body mass index
242	(BMI) was 22.66 kg/m ² , and islet autoantibodies were all negative. Initial FBG was
243	6–7 mmol/L, 2hBG was 15–18 mmol/L, and HbA1c was 113.12 mmol/mol (12.5%).
244	The result of the 75g oral glucose tolerance test (OGTT) confirmed the diagnosis of
245	diabetes and indicated the presence of insulin resistance and inadequate insulin
246	secretion in response to glucose load. (Fig. 1a). She was treated with Metformin (0.5 g
247	TID) and Insulin glargine (18 U QN), with occasional monitoring showing FBG of 5–
248	7 mmol/L and 2hBG of 13-14 mmol/L. She continued this treatment inconsistently,
249	without dietary control, regular exercise, or routine SMBG. After 2.5 years, she
250	discontinued insulin and continued Metformin (0.5 g TID), with occasional FBG
251	readings of 6-7 mmol/L. Five years post-diagnosis, her FBG increased to 7.5-13.2
252	mmol/L, HbA1c to 132.79 mmol/mol (14.3%), and BMI to 26.76 kg/m ² . Her regimen
253	was changed to Metformin (0.5 g TID), Insulin aspart (8-6-6 U before meals), and
254	Insulin glargine (12-16 U QN), but glycemic control remained poor, with FBG of 7-

10 mmol/L. Her father was diagnosed with diabetes at thirties, treated with Metformin 255 0.5 g BID and Vildagliptin 50 mg BID, with FBG of 5-7 mmol/L. Seven years later, 256 his regimen was changed to Metformin 0.5 g TID and occasional Dapagliflozin, 257 maintaining FBG at 6.5 mmol/L and HbA1c at 60.66 mmol/mol (7.7%). Her 258 grandfather was diagnosed with diabetes at fifties, managed with oral hypoglycemic 259 agents. Her mother was found to have pre-diabetes at forties based on blood glucose 260 and HbA1c levels. Clinical details of the proband and her family were summarized in 261 Table 1. 262 Given the proband's negative islet autoantibodies and family history, we suspected 263 monogenic diabetes and performed genetic screening. DNA sequencing revealed a 264 novel heterozygous missense mutation, c.77A>T, in exon 2 of the GCK gene, 265 resulting in a glutamine-to-leucine substitution at position 26 (p.Q26L), which had not 266 been reported yet. According to American College of Medical Genetics and Genomics 267 (ACMG) and the Association for Molecular Pathology (AMP) in 2015 guidelines, the 268 mutation was classified as a variant of uncertain significance (VUS) with evidence 269 270 PM1+PM2+PP2. Pedigree analysis showed that the proband's father had the same 271 heterozygous mutation, while the grandfather and mother did not (Fig. 1b, c). Based on these findings, the proband's diabetes type and the role of the GCK-Q26L 272 mutation in her complex diabetic phenotype remain unclear. However, the father's 273

274 glycemic profile aligned with typical GCK-MODY characteristics. Therefore, further

experiments were conducted to assess the impact of the GCK mutation on proteinfunction.

277

278	GCK-Q26L is a GCK-MODY causing mutation. Since GCK-Q26L was classified
279	as a VUS and the proband presented atypical clinical features of GCK-MODY, it
280	remained to be determined whether GCK-Q26L is a diabetes causing mutation. We
281	therefore established a global knock-in mouse model expressing MYC-tagged GCK-
282	Q26L (ESM Fig. 1a). Western blot confirmed the specific expression of MYC-tagged
283	mutant GCK in the liver and islets in a dose-dependent manner in GCK-Q26L
284	heterozygous (Het) and homozygous (Hom) mice (ESM Fig. 1b). We had monitored
285	body weight (BW) and FBG of mutant and wild-type (WT) male mice for 16 weeks.
286	Although the GCK-Q26L mutation did not affect BW, it caused mild, non-progressive
287	elevation of FBG in Het mice, with further elevation observed in Hom mice (Fig. 2a,
288	b). To investigate whether abnormal circulating levels of insulin or glucagon were
289	associated with elevated FBG, we examined fasting serum insulin and glucagon levels.
290	Our findings showed that although glucagon levels were unaffected, serum insulin
291	levels were decreased in 16-week-old mutant mice (Fig. 2c, d). We therefore
292	performed intraperitoneal glucose tolerance test (IPGTT) and found that Het and Hom
293	mice exhibited significantly impaired glucose tolerance and lower serum insulin
294	levels compared to that of WT mice at 3 weeks of age (Fig. 2e, f). The severities of

295	decreased serum insulin and impaired glucose tolerance did not further worsen in 16-
296	week-old mutant mice (Fig. 2g, h). The phenotype of female mice was similar to that
297	of male mice but less severe (ESM Fig. 2). These data established that GCK-Q26L
298	caused non-progressive mild hyperglycemia representing one of classic clinical
299	features of GCK-MODY, confirming that GCK-Q26L is a GCK-MODY mutation.

300

GCK-O26L does not affect insulin sensitivity and islet insulin content. Since GCK 301 is also expressed in hepatocytes, we asked whether GCK-Q26L affected insulin 302 sensitivity. We performed intraperitoneal insulin tolerance test (IPITT) and found that 303 304 GCK mutant did not affect insulin sensitivity (Fig. 3a, b), suggesting that hyperglycemia was mainly due to decreased circulating insulin. To investigate 305 whether reduced serum insulin in Het and Hom male mice is caused by decreased to 306 islet insulin content or insulin secretion, we measured insulin content by two 307 independent approaches (western blots and insulin enzyme-linked immunosorbent 308 assays, ELISA). Both methods consistently showed no substantial differences in 309 insulin content in islets of Het and Hom mice compared to WT mice (Fig. 3c-f). The 310 ratio of proinsulin-to-insulin was also not affected (Fig. 3f). Immunofluorescence 311 analysis revealed no impact of the mutation on the abundance and intraislet 312 composition of insulin-positive, glucagon-positive, and somatostatin-positive cells 313 314 among three groups (Fig. 3h). Furthermore, western blot results showed no significant

differences in endogenous GCK protein expression in the islets among the three
groups, indicating that the GCK-Q26L did not affect protein levels of endogenous
GCK (Fig. 3d, g).

318

GCK-Q26L impairs glucose-stimulated insulin secretion without affecting 319 potassium-stimulated insulin secretion and glucose-inhibited glucagon secretion. 320 321 Since the GCK-Q26L caused a decrease of circulating insulin without affecting islet insulin content (Fig. 2-3), we next asked whether it impair insulin secretion. Insulin 322 secretion was monitored in isolated islets exposed to different glucose concentrations 323 324 (2.8 mM, 3.3 mM, 4.5 mM, 5.6 mM, 7 mM). We found that the curve of glucose concentration-dependent insulin secretion was shifted to right in Het mice (Fig. 4a), 325 suggesting that the glucose threshold for insulin secretion was increased in GCK-326 O26L mice. In addition, insulin secretion response to even higher glucose (16.7 mM) 327 was also impaired in Het islets and the response was further diminished in Hom islets 328 (Fig. 4b). Islet perfusion tests with different glucose concentrations further supported 329 these observations (Fig. 4c). However, despite defects in response to glucose, GCK-330 Q26L did not affect insulin secretion response to potassium in both tests of potassium 331 chloride-stimulated insulin secretion (KSIS) and islet perfusion (Fig. 4d, e). 332 Furthermore, no differences were observed in glucose-inhibited glucagon secretion 333 334 (GIGS) in Het and Hom mutant mice (Fig. 4f). These data demonstrated that GCK-

335 Q26L impaired the function of GCK as a glucose sensor in β cells, impeding GSIS
336 without affecting KSIS and GIGS.

337

338	Dorzagliatin restores the glucose threshold for insulin secretion and ameliorates
339	glucose tolerance in GCK-Q26L mice. Dorzagliatin, a novel allosteric glucokinase
340	activator (GKA), improved glycaemic control and was approved in China for the
341	treatment of adult patients with type 2 diabetes [23, 24]. To evaluate the effects of
342	dorzagliatin on insulin secretion and glucose tolerance in GCK-Q26L mice, we firstly
343	treated mice with oral administrations of dorzagliatin, measured fasting blood glucose
344	and insulin levels 90 minutes after treatment, and then performed IPGTT. We found
345	that dorzagliatin significantly decreased FBG and increased fasting insulin levels in
346	both WT, Het, and Hom mutant mice (Fig. 5a, b). IPGTT results further confirmed
347	improvement of glucose tolerance in mutant mice treated with dorzagliatin (Fig. 5c).
348	We further analyzed insulin secretion response glucose and found that dorzagliatin
349	restored the glucose threshold for insulin secretion (Fig. 5d) and improved GSIS (Fig.
350	5e) in GCK-Q26L mutant islets.

351

352 Liraglutide amplifies insulin secretion response to glucose and ameliorates
353 glucose tolerance in GCK-Q26L mice. Since liraglutide, a glucagon-like peptide-1
354 receptor agonist (GLP-1RA), has an effect of glucose-dependent stimulated insulin

secretion, we next asked whether liraglutide could show beneficial effects on insulin 355 secretion and glucose tolerance in GCK-Q26L mice. We conducted similar 356 experiments as dorzagliatin treatment shown in Fig. 5. We found that unlike 357 dorzagliatin, liraglutide did not significantly stimulate insulin secretion in the fasting 358 state both in WT and mutant mice, and only moderately decreased FBG in GCK 359 mutant mice compared with dorazgliatin (Fig. 6a, b). However, liraglutide indeed 360 markedly stimulated insulin secretion and decreased blood glucose 15 minutes after 361 glucose load (Fig. 6c, d), ameliorating overall glucose tolerance (Fig. 6e). In vitro 362 experiments using isolated islets further confirmed that liraglutide improved GSIS 363 (Fig. 6f) and amplified insulin secreation in 5.6 mmol/L glucose (Fig. 6g) in islets 364 from GCK-Q26L mice. Altogether, these results suggest that while both dorzagliatin 365 and liraglutide improve glucose homeostasis, they do so through distinct mechanisms. 366 Dorzagliatin directly enhances the glucose-sensing capability of glucokinase, whereas 367 liraglutide amplifies insulin secretion in response to glucose. 368

369

A high PRS for insulin resistance is associated with atypical and more severe diabetic phenotypes in proband. The experimental evidence above demonstrates that GCK-Q26L is a GCK-MODY causing mutation. However, although the proband inherited the mutation from her father who presented typical clinical features of GCK-MODY, the proband presented more severe hyperglycemia that did not resemble a

classic GCK-MODY (Fig. 1 and Table 1), suggesting that additional factors may 375 contribute to phenotypes of the proband. Indeed, as the disease progressed, the 376 proband became overweight (BMI 26.76 kg/m²) and developed dyslipidemia with a 377 high Triglyceride (TG) to HDL-cholesterol (HDL-c) ratio, conditions often associated 378 with insulin resistance [19]. Utilizing data from 424,068 individuals in the UK 379 380 Biobank (UKB), we examined the association between the TG/HDL-c ratio, a surrogate measure of insulin resistance [9, 16-19], with insulin resistance polygenic 381 scores. Results indicated the PRS was significantly associated with the observed 382 383 TG/HDL-c ratio, that higher PRS levels corresponded with increases in the TG/HDLc ratio, supporting the relevance of PRS in assessing insulin resistance genetic risk in 384 the population (Fig. 7a). To explore the genetic predisposition of insulin resistance in 385 this family, we conducted a PRS analysis and used the East Asian samples from the 386 1000 Genomes Project samples for evaluate the PRS risk and adjusted for potential 387 population structure confounding through principal component analysis (PCA) (ESM 388 Fig. 5a, b). The PRS analysis of the family indicated the proband inherited a high 389 390 insulin resistance genetic risk from her mother, who has an IR PRS score ranked in the top 2% in the study population (Fig. 7b). According to previous studies, 391 monogenic risk and polygenic scores may jointly influence the risk of disease [14]. 392 393 These data suggest that the probands' atypical and severe diabetic phenotypes were associated with high PRS for insulin resistance in addition to GCK mutation. 394

395

396 **Discussion**

397 The identification of the novel GCK-Q26L mutation, originally classified as VUS, in two members of a family with marked differences in PRS for insulin resistance and 398 different severities of diabetes adds to the growing complexities of genetic 399 contributions to the development and progression of diabetes. With multiple 400 independent approaches, we demonstrated that GCK-Q26L did not affect insulin 401 biosynthesis and islet insulin content, but impeded glucose sensing of pancreatic β 402 cells, increasing the threshold of glucose concentration for insulin secretion, impairing 403 GSIS, and therefore causing mild elevated FBG and glucose intolerance. These data 404 established that GCK-Q26L is indeed a pathogenic mutation causing GCK-MODY. 405

406

GCK-MODY typically presents with mild hyperglycemia that is often managed 407 without pharmacological intervention due to low risks of diabetes related chronic 408 complications and the limited efficacy of traditional glucose-lowering medications [4, 409 6]. However, the presence of insulin resistance can complicate the clinical picture, 410 leading to more severe hyperglycemia and necessitating therapeutic intervention. The 411 412 results from our GCK-Q26L mouse model highlight the potential therapeutic benefits of using GKA and GLP-1RAs in managing diabetes phenotypes influenced by both 413 GCK mutations and polygenic risk factors for insulin resistance. Dorzagliatin is a new 414 415 a dual-acting GKA that enhances glucokinase activity by binding to its allosteric site,

increasing glucose phosphorylation and insulin secretion, thereby improving glycemic 416 control [23, 25]. In a clinical trial, dorzagliatin directly increases insulin secretion and 417 glucose sensitivity in patients with GCK-MODY, suggesting that it may be able to 418 preserve GCK activity in GCK-MODY [26]. Our data further demonstrated that 419 dorzagliatin restored glucose threshold for insulin secretion and improved GSIS and 420 glucose intolerance in GCK-Q26L mutant mice (Fig, 5d-e). It is worthy to note that 421 dorzagliatin can increase insulin secretion in GCK-Q26L mice and decrease blood 422 glucose even in the fasting state with relatively low FBG in both WT and mutant mice 423 (Fig. 5a-c). However, there is no increased risk of hypoglycemia in a phase 3 clinical 424 trial dorzagliatin [23]. It remains to be determined whether this was caused by extra 425 high dose of dorzagliatin (about 15 times higher dose using in mice in this study than 426 recommend dose for patients with type 2 diabetes) or due to different responses of 427 different species. 428

429

In addition to dorzagliatin that directly targets to GCK, GLP-1RAs may also be considered for the management of patients with GCK-MODY due to its beneficial effect on glucose-dependent insulin secretion. Indeed, our data demonstrated that liraglutide enhanced glucose sensing of mutant islets at physiological glucose concentrations and improved GSIS (Fig. 6). Furthermore, one signal administration of liraglutide could significantly decrease FBG of mutant mice without affecting FBG of

WT mice and markedly improve glucose tolerance (Fig, 6). These beneficial effects on glucose sensing and insulin secretion along with its role in regulating weight loss and insulin resistance make liraglutide (and may be other GLP1-RAs) an attractive option for the management of GCK-MODY, especially in patients with GCK-MODY with insulin resistance.

441

To date, monogenic mutation involved in more than 70 genes have been identified to 442 cause monogenic diabetes. Some of the biggest challenges for early recognition and 443 diagnosis of monogenic diabetes are highly variable for disease penetrance and 444 445 clinical presentations in patients carrying different mutations in one gene or even the same mutation in the same gene. Accumulating evidence indicates that genetic and/or 446 environmental factors may exacerbate or lessen the conditions, and many VUS can 447 have significant pathogenic effects when combined with other genetic predispositions 448 [4, 27]. In the current study, we found that the proband who carried a GCK-MODY 449 causing mutation inherited from her father, also possessed a high PRS for insulin 450 resistance that may have been inherited in part from her mother, whose PRS for 451 insulin resistance was in top 1.09th percentile (Fig. 7). The elevated PRS may 452 contribute to proband's atypical presentation including more severe hyperglycemia 453 and dyslipidemia, supporting an additive effect that monogenic and polygenic factors 454 455 may interact. These findings align with recent research indicating that PRS can

substantially influence the clinical presentation of monogenic diseases, including 456 diabetes [28, 29]. This dual influence underscores the complexity of diabetes 457 458 pathogenesis and challenges the traditional dichotomy between monogenic and polygenic diabetes, highlighting the importance of considering polygenic factors even 459 in cases initially attributed to single-gene mutations [30, 31]. Incorporating 460 461 comprehensive genetic assessments, including PRS, into routine diabetes care could revolutionize how we predict, diagnose, and manage diabetes. Recognizing the role of 462 PRS might help identify individuals at high risk for severe forms of diabetes, 463 facilitating earlier interventions and more personalized management strategies [32]. 464 Additionally, understanding the interplay between different genetic factors could lead 465 to the development of targeted therapies that address specific mechanistic pathways 466 involved in the disease [33, 34]. Recent studies have demonstrated the potential of 467 such personalized approaches in improving disease prognosis [35]. 468

469

Despite these promising findings, several limitations need to be acknowledged. First, the study's reliance on a mouse model may not fully capture the complexity of human GCK-MODY and its interaction with insulin resistance. While the GCK-Q26L mutant mouse model provides valuable insights, human clinical trials are essential to validate the efficacy and safety of GKA and GLP-1RAs in GCK-MODY individuals with or without insulin resistance. Second, the study did not explore the long-term effects of

these treatments on beta-cell function and overall metabolic health. Longitudinal studies are necessary to understand the potential benefits and risks associated with chronic use of these therapies. Third, the sample size and genetic diversity of the study population were limited. Future research should include larger, more diverse cohorts to ensure the generalizability of the findings. Furthermore, exploring geneenvironment interactions will be crucial in elucidating the full impact of monogenic and polygenic factors on the development and progression of monogenic diabetes.

483

484 Author contributions

SJ, HS, and HZ designed and conducted experiments and analyzed data; SJ, HS, HZ
YY, XL, SC, WF, JQ, JZ, and ZZ conducted experiments; All other authors revised
the manuscript critically for important intellectual content. MW discussed project and
edited manuscript; ML initiated and oversaw the project, designed the experiments,
and wrote the manuscript.

490 Acknowledgments

The work was supported by the National Key R&D Program (2022YFE0131400 and 2019YFA0802502), and also by the National Natural Science Foundation of China (82220108014). We acknowledge the support of Tianjin Municipal Health Commission (TJWJ2021ZD001), Tianjin Medical University General Hospital Clinical Research Program (22ZYYLCZD02), Tianjin Municipal Science and

496	Technology Commission (23JCQNJC00680 and 23JCQNJC00670), National Natural
497	Science Foundation of China (82200892, 82301951, and 81800733), Tianjin
498	Municipal Education Commission (2021KJ209), Tianjin Medical University
499	Endocrine and Metabolic Disease the Youth Talent Incubator Program
500	(2024XKNFM13), Tianjin Key Medical Discipline (Specialty) Construction Project
501	(TJYXZDXK-030A), and Tianjin Medical University Clinical Special Disease
502	Research Center - Neuroendocrine Tumor Clinical Special Disease Research Center.

503 Data availability

504	Due to local privacy laws and privileged human information, all requests for raw
505	genotyping and clinical data are subject to prior approval from the local IRB. Analysis
506	of the UK Biobank data was performed using application 89885. The UK Biobank
507	data are available to researchers with research inquiries following IRB and UK
508	Biobank approval (https://www.ukbiobank.ac.uk/enableyour-research/apply-for-
509	access). The polygenic scores described in this publication are available for download
510	from the Polygenic Score Catalog (https:// www.pgscatalog.org) under the publication
511	ID PGP000223

512 Code availability

513 The manuscript described a pragmatic approach of publicly available software.

514 Additional code is available upon request from the authors.

515 **References**

- 516 [1] Matschinsky FM (1990) Glucokinase as glucose sensor and metabolic signal generator in
- 517 pancreatic beta-cells and hepatocytes. Diabetes 39(6): 647-652. 10.2337/diab.39.6.647
- 518 [2] Grimsby J, Sarabu R, Corbett WL, et al. (2003) Allosteric activators of glucokinase: potential 519 role in diabetes therapy. Science 301(5631): 370-373. 10.1126/science.1084073
- 520 [3] Matschinsky FM (2002) Regulation of pancreatic beta-cell glucokinase: from basics to 521 therapeutics. Diabetes 51 Suppl 3: S394-404. 10.2337/diabetes.51.2007.s394
- 522 [4] Stride A, Vaxillaire M, Tuomi T, et al. (2002) The genetic abnormality in the beta cell
 523 determines the response to an oral glucose load. Diabetologia 45(3): 427-435. 10.1007/s00125524 001-0770-9
- 525 [5] Osbak KK, Colclough K, Saint-Martin C, et al. (2009) Update on mutations in glucokinase 526 (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and 527 hyperinsulinemic hypoglycemia. Hum Mutat 30(11): 1512-1526. 10.1002/humu.21110
- 528 [6] Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT (2014) Prevalence of
 529 vascular complications among patients with glucokinase mutations and prolonged, mild
 530 hyperglycemia. JAMA 311(3): 279-286. 10.1001/jama.2013.283980
- 531 [7] Chakera AJ, Steele AM, Gloyn AL, et al. (2015) Recognition and Management of Individuals
 532 With Hyperglycemia Because of a Heterozygous Glucokinase Mutation. Diabetes Care 38(7):
 533 1383-1392. 10.2337/dc14-2769
- 534 [8] Lotta LA, Gulati P, Day FR, et al. (2017) Integrative genomic analysis implicates limited
 535 peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet
 536 49(1): 17-26. 10.1038/ng.3714
- 537 [9] Oliveri A, Rebernick RJ, Kuppa A, et al. (2024) Comprehensive genetic study of the insulin
 538 resistance marker TG:HDL-C in the UK Biobank. Nat Genet 56(2): 212-221. 10.1038/s41588-023539 01625-2
- 540 [10] Suzuki K, Hatzikotoulas K, Southam L, et al. (2024) Genetic drivers of heterogeneity in type 2
 541 diabetes pathophysiology. Nature 627(8003): 347-357. 10.1038/s41586-024-07019-6
- [11] Khera AV, Chaffin M, Aragam KG, et al. (2018) Genome-wide polygenic scores for common
 diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 50(9):
 1219-1224. 10.1038/s41588-018-0183-z
- 545 [12] Schroeder P, Mandla R, Huerta-Chagoya A, et al. (2023) Rare variant association analysis in
 546 51,256 type 2 diabetes cases and 370,487 controls informs the spectrum of pathogenicity of
 547 monogenic diabetes genes. medRxiv. 10.1101/2023.09.28.23296244
- 548 [13] Kingdom R, Beaumont RN, Wood AR, Weedon MN, Wright CF (2024) Genetic modifiers of

549 rare variants in monogenic developmental disorder loci. Nat Genet 56(5): 861-868.
550 10.1038/s41588-024-01710-0

- 551 [14] Fahed AC, Wang M, Homburger JR, et al. (2020) Polygenic background modifies penetrance
- of monogenic variants for tier 1 genomic conditions. Nat Commun 11(1): 3635. 10.1038/s41467020-17374-3
- 554 [15] McCarthy MI (2017) Painting a new picture of personalised medicine for diabetes.
 555 Diabetologia 60(5): 793-799. 10.1007/s00125-017-4210-x
- [16] Iwani NA, Jalaludin MY, Zin RM, et al. (2017) Triglyceride to HDL-C Ratio is Associated with
 Insulin Resistance in Overweight and Obese Children. Sci Rep 7: 40055. 10.1038/srep40055
- [17] McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G (2003) Use of metabolic
 markers to identify overweight individuals who are insulin resistant. Ann Intern Med 139(10):
 802-809. 10.7326/0003-4819-139-10-200311180-00007
- [18] Pantoja-Torres B, Toro-Huamanchumo CJ, Urrunaga-Pastor D, et al. (2019) High
 triglycerides to HDL-cholesterol ratio is associated with insulin resistance in normal-weight
 healthy adults. Diabetes Metab Syndr 13(1): 382-388. 10.1016/j.dsx.2018.10.006
- 564 [19] Chiang JK, Lai NS, Chang JK, Koo M (2011) Predicting insulin resistance using the
 565 triglyceride-to-high-density lipoprotein cholesterol ratio in Taiwanese adults. Cardiovasc
 566 Diabetol 10: 93. 10.1186/1475-2840-10-93
- 567 [20] Das S, Forer L, Schonherr S, et al. (2016) Next-generation genotype imputation service and
 568 methods. Nat Genet 48(10): 1284-1287. 10.1038/ng.3656
- 569 [21] Purcell S, Neale B, Todd-Brown K, et al. (2007) PLINK: a tool set for whole-genome
 570 association and population-based linkage analyses. Am J Hum Genet 81(3): 559-575.
 571 10.1086/519795
- 572 [22] Qiao J, Zhang Z, Ji S, et al. (2022) A distinct role of STING in regulating glucose homeostasis
 573 through insulin sensitivity and insulin secretion. Proc Natl Acad Sci U S A 119(7).
 574 10.1073/pnas.2101848119
- 575 [23] Zhu D, Li X, Ma J, et al. (2022) Dorzagliatin in drug-naive patients with type 2 diabetes: a
 576 randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 28(5): 965-973.
 577 10.1038/s41591-022-01802-6
- 578 [24] Syed YY (2022) Dorzagliatin: First Approval. Drugs 82(18): 1745-1750. 10.1007/s40265-022579 01813-0
- 580 [25] Haddad D, Dsouza VS, Al-Mulla F, Al Madhoun A (2024) New-Generation Glucokinase
 581 Activators: Potential Game-Changers in Type 2 Diabetes Treatment. Int J Mol Sci 25(1).
 582 10.3390/ijms25010571
- 583 [26] Chow E, Wang K, Lim CKP, et al. (2023) Dorzagliatin, a Dual-Acting Glucokinase Activator,

Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the
Young and Recent-Onset Type 2 Diabetes. Diabetes 72(2): 299-308. 10.2337/db22-0708

- 586 [27] Richards S, Aziz N, Bale S, et al. (2015) Standards and guidelines for the interpretation of
 587 sequence variants: a joint consensus recommendation of the American College of Medical
 588 Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5): 405-424.
- 589 10.1038/gim.2015.30
- 590 [28] Khera AV, Chaffin M, Wade KH, et al. (2019) Polygenic Prediction of Weight and Obesity
 591 Trajectories from Birth to Adulthood. Cell 177(3): 587-596 e589. 10.1016/j.cell.2019.03.028
- 592 [29] Johansson S, Irgens H, Chudasama KK, et al. (2012) Exome sequencing and genetic testing
 593 for MODY. PLoS One 7(5): e38050. 10.1371/journal.pone.0038050
- 594 [30] Udler MS, McCarthy MI, Florez JC, Mahajan A (2019) Genetic Risk Scores for Diabetes
 595 Diagnosis and Precision Medicine. Endocr Rev 40(6): 1500-1520. 10.1210/er.2019-00088

596 [31] Bonnefond A, Semple RK (2022) Achievements, prospects and challenges in precision care
597 for monogenic insulin-deficient and insulin-resistant diabetes. Diabetologia 65(11): 1782-1795.
598 10.1007/s00125-022-05720-7

- 599 [32] Pearson ER, Velho G, Clark P, et al. (2001) beta-cell genes and diabetes: quantitative and
 600 qualitative differences in the pathophysiology of hepatic nuclear factor-1alpha and glucokinase
 601 mutations. Diabetes 50 Suppl 1: S101-107. 10.2337/diabetes.50.2007.s101
- 602 [33] McCarthy MI (2010) Genomics, type 2 diabetes, and obesity. N Engl J Med 363(24): 2339603 2350. 10.1056/NEJMra0906948
- 604 [34] Le Collen L, Froguel P, Bonnefond A (2024) Towards the recognition of oligogenic forms of
 605 type 2 diabetes. Trends Endocrinol Metab. 10.1016/j.tem.2024.06.006
- 606 [35] Inshaw JRJ, Cutler AJ, Crouch DJM, Wicker LS, Todd JA (2020) Genetic Variants Predisposing
 607 Most Strongly to Type 1 Diabetes Diagnosed Under Age 7 Years Lie Near Candidate Genes That
 608 Function in the Immune System and in Pancreatic beta-Cells. Diabetes Care 43(1): 169-177.
 609 10.2337/dc19-0803
- 610
- 611
- 612

613



2 Figure 1. Proband with impaired insulin secretion and diabetes carries a GCK missense 3 mutation (c.77A>T, p.Q26L) that was inherited from her father. (a) The results of blood 4 glucose, insulin, and C-Peptide of the proband during OGTT performed at the onset of diabetes. (b) 5 A missense mutation in GCK gene (c.77A>T, p.Q26L) was identified in the proband and her 6 father by WES confirmed by Sanger sequencing. (c) Pedigree analyses showed that GCK-Q26L 7 was inherited from proband's father. Squares represent males and circles represent females. Filled 8 black symbols indicated members affected with diabetes, gray symbol represented the member 9 with the pre-diabetes. The proband was indicated with a black arrow. Where tested, the genotypes 10 of family members were given (N, normal allele; M, mutant allele; NN, normal genotype; NM,

1

11 heterozygous genotype).





13 Figure 2. GCK-Q26L causes glucose intolerance in a dose-dependent manner. (a, b) Body 14 weight (a) and fasting blood glucose (b) of male mice were measured at 3, 8, 12, 16 weeks of age. WT vs Het, WT vs Hom, ** P < 0.01, *** P < 0.001, **** P < 0.0001. (c) Fasting serum insulin in 15 16 three-group 16-week-old male mice were measured by ELISA. (d) Fasting serum glucagon in 17 three-group 16-week-old male mice were measured by ELISA. (e) IPGTT in 3-week-old male 18 mice (2 g/kg i.p.) and the area under curve (AUC) of blood glucose during IPGTT. (f) Serum 19 insulin levels in 3-week-old male mice during IPGTT were measured by ELISA, with calculated 20 AUCs. (g) IPGTT in 16-week-old male mice (2 g/kg i.p) and the AUC of blood glucose. (h) 21 Serum insulin levels in 16-week-old male mice during IPGTT were measured by ELISA, with 22 calculated AUCs. Each data point represents an individual mouse. Values are shown as mean \pm 23 SEM. WT vs Het, WT vs Hom, Het vs Hom, *P < 0.05, **** P < 0.0001.

24





Figure 3. GCK-Q26L did not affect insulin sensitivity, insulin content, and islet cell 26 27 composition. (a, b) IPITT were performed in 16-week-old male mice (0.7 U/kg i.p), (b) was (a) 28 normalized to the baseline of blood glucose. (c) Islet insulin content of 16-week-old male mice 29 was measured by ELISA. (d) Islets isolated from 10-week-old male mice were directly lysed. 30 Western blots were performed to detect endogenous GCK, MYC-tagged GCK (GCK-MYC), 31 proinsulin and insulin as indicated. GAPDH was used as a loading control. Quantification of 32 insulin (e), the ratio of proinsulin to insulin (f), and GCK (g). (h) Representative 33 immunofluorescence images of anti-insulin (red), anti-glucagon (green) and

- 34 anti-somatostatin(green) antibodies in pancreatic sections from 12-week-old male mice. Scale bar
- $35 = 50 \ \mu m \ (n = 3 \ mice/group)$. Each data point represents an individual mouse. Values were shown
- 36 as mean \pm SEM.



Figure 4. GCK-Q26L impaired glucose-stimulated insulin secretion without affecting potassium-stimulated insulin secretion and glucose-inhibited glucagon secretion. (a) Dose-dependent effects of glucose on insulin secretion of 16-week-old male WT and Het mice. Isolated islets successively incubated in 2.8, 3.3, 4.5, 5.6 and 7 mmol/L glucose. (b) Islets isolated from 10-week-old male WT, Het and Hom mice were incubated with 2.8 mmol/L for 1 hour followed by stimulated with either low (2.8 mmol/L) or high (16.7 mmol/L) glucose for 2 hours. Insulin secretion response to low and high glucose were measured. (c, e) Dynamic insulin secretion of 10-week-old male WT and Hom mice islets cultured in the perfusion chamber with continues buffer renewal (2.8 mmol/L glucose, 16.7 mmol/L glucose, 2.8 mmol/L glucose, 30 mmol/L potassium), with calculated AUCs. (d) Islets isolated from 10-week-old male WT, Het and Hom mice were incubated with 2.8 mmol/L glucose for 1 hour followed by stimulated with either low (3.3 mmol/L) or high (50 mmol/L) potassium for 2 hours. Insulin secretion response to low and high potassium were measured. (f) Glucagon secretion measured in isolated islets from 10-week-old male WT, Het and Hom mice when incubated in 2.8 and 16.7 mmol/L glucose. Each data point represents an individual mouse. Values are shown as mean \pm SEM. * P < 0.05.



Figure 5. Dorzagliatin (GKA) restores the glucose threshold for insulin secretion and ameliorates glucose tolerance in GCK-Q26L mice. (a-c) We performed IPGTT on 10-week-old male mice (2 g/kg i.p), and vehicle (0.9% Nacl) or GKA (30 mg/kg) was administered orally to mice 90 minutes before glucose challenge. Blood glucose (a) and serum insulin level (b) before glucose challenge. (c) Blood glucose and AUC of IPGTT. (d) Dose-dependent effects of glucose on insulin secretion of 10-week-old male WT and Het mice with or without 30 uM GKA, and the AUC of Insulin secretion. Het *vs* Het-GKA, *P < 0.05. (e) Insulin secretion measured in isolated islets from 10-week-old male WT, Het and Hom mice when incubated in 2.8, 16.7 mmol/L glucose and 16.7 mmol/L glucose containing 30 uM GKA. Each data point represents an individual mouse. Values are shown as mean \pm SEM. * P < 0.05, ** P < 0.01, **** P < 0.0001.





Figure 6. Liraglutide amplifies insulin secretion response to glucose and ameliorates glucose tolerance in GCK-O26L mice. (a, b) For liraglutide, we conducted experiments similar to those shown in Figure 5 with dorzagliatin, assessing blood glucose (a) and serum insulin levels (b) in mice that had been treated with dorzagliatin and liraglutide prior to glucose challenge. (c-e) show the results of IPGTT with Liraglutide. Blood glucose (c) and serum insulin level (d) 15 minutes after glucose challenge. (e) IPGTT and the AUC of blood glucose. (f) Insulin secretion measured in isolated islets from 10-week-old male WT, Het and Hom mice when incubated in 2.8, 16.7 mmol/L glucose and 16.7 mmol/L glucose containing 100 nM Lira. (g) Dose-dependent effects of glucose on insulin secretion and the AUC of 10-week-old male WT and Het mice with or without 100 nM Lira, Het vs Het-Lira, * P < 0.05. Each data point represents an individual mouse. Values are shown as mean \pm SEM. * P < 0.05 *** P < 0.001, **** P < 0.0001.



Figure 7. Quality control and PRS score for study samples. (**a**) The distribution of the ratio of triglycerides to HDL cholesterol as a function of quintiles of an insulin resistance (IR) polygenic risk score (PRS) was evaluated in 424,664 UK Biobank samples. The horizontal line in the box indicates the median value, and the top and bottom of the box indicate the upper and lower quartiles, respectively. (**b**) The results of insulin resistance polygenic risk score analysis on case family. The curve denotes the probability density function of the IR PRS scores from the 1000 Genomes Project East Asian samples. Vertical dashed lines indicate the PRS for each family member: the father's position at the top 46.96th percentile, the proband at the top 28.52th percentile, and the mother at the top 1.09th percentile.

	Proband	Father	Mother
Age at diagnosis	Teens	Thirties	/
Gender	Female	Male	Female
BMI at present (kg/m ²)	26.76	25.54	29.78
Clinical symptoms at onset	Polydipsia, polyuria, polyphagia, weight loss and ketosis	found elevated FBG in a physical examination	/
FBG at diagnosis (mmol/L)	6-7	5-7	/
FBG at present (mmol/L)	7.5-13.2	6.5	6.4
HbA1c at diagnosis (mmol/mol)	113.12 (12.5%)	/	/
HbA1c at present (mmol/mol)	132.79 (14.3%)	60.66 (7.7%)	44.26 (6.2%)
Total cholesterol (mmol/L)	5.85	5.44	4.19
Triglycerides (mmol/L)	10.39	0.80	1.11
HDL-cholesterol (mmol/L)	0.74	1.03	0.78
LDL-cholesterol (mmol/L)	3.88	3.90	3.24
Islet autoantibodies	Negative	/	/
Treatment at diagnosis	Metformin 0.5g TID	Metformin 0.5g BID	/

Table 1. Clinical features of the family of the proband carrying GCK(Q26L) mutation

	Insulin glargine: 18U QN	Vildagliptin 50mg BID	
Treatment at present	Metformin 0.5g TID Insulin aspart: 8-6-6U Insulin glargine: 12U QN	Metformin 0.5g BID	/
Complications and comorbidities	No	Diabetic retinopathy (non-proliferative stage)	/

Note: BMI, body mass index; FBG, fasting blood glucose; HDL, high density lipoprotein; LDL, low density lipoprotein; OGTT, oral glucose tolerance test; OHA, oral hypoglycemic agent; Islet autoantibodies, GADA(glutamate decarboxylase antibody), ICA(islet cell antibody), IA-2A(protein tyrosine phosphatase-like protein antigen), ZnT8A(Zinc transporter 8 antibody); TID, ter in die; BID, bis in die; QN, quāque nocte; "/", none or not provided.